Tubastatin A is primarily used as a selective inhibitor of histone deacetylase 6 (HDAC6), making it a valuable tool in epigenetic research. It is widely applied in studies related to neurodegenerative diseases such as Alzheimer's and Parkinson’s, where HDAC6 inhibition has been shown to improve microtubule stability and enhance transport in neurons. It also demonstrates potential in cancer research by inducing apoptosis and inhibiting tumor cell proliferation, especially in combination with other anticancer agents. Additionally, Tubastatin A has been investigated for its anti-inflammatory effects, modulating immune responses through suppression of pro-inflammatory cytokines. Its ability to cross the blood-brain barrier further enhances its utility in central nervous system disease models.